EP4021912A4 - Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer - Google Patents
Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer Download PDFInfo
- Publication number
- EP4021912A4 EP4021912A4 EP20857153.9A EP20857153A EP4021912A4 EP 4021912 A4 EP4021912 A4 EP 4021912A4 EP 20857153 A EP20857153 A EP 20857153A EP 4021912 A4 EP4021912 A4 EP 4021912A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- prodrugs
- tyrosine kinase
- kinase inhibitor
- treating cancer
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910818779.0A CN112442011B (zh) | 2019-08-30 | 2019-08-30 | 一种前药化合物及其在治疗癌症方面的应用 |
| CN201910818675.XA CN112442010B (zh) | 2019-08-30 | 2019-08-30 | 一类前药化合物及其在治疗癌症方面的应用 |
| CN201910817505.XA CN112442009B (zh) | 2019-08-30 | 2019-08-30 | 氘代化合物及其在治疗癌症方面的应用 |
| US202062994364P | 2020-03-25 | 2020-03-25 | |
| PCT/CA2020/051177 WO2021035360A1 (fr) | 2019-08-30 | 2020-08-28 | Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4021912A1 EP4021912A1 (fr) | 2022-07-06 |
| EP4021912A4 true EP4021912A4 (fr) | 2023-08-23 |
Family
ID=74684795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20857153.9A Pending EP4021912A4 (fr) | 2019-08-30 | 2020-08-28 | Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4021912A4 (fr) |
| AU (1) | AU2020338490A1 (fr) |
| CA (1) | CA3147801A1 (fr) |
| IL (1) | IL290798A (fr) |
| WO (1) | WO2021035360A1 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106317017A (zh) * | 2015-07-10 | 2017-01-11 | 李建成 | 一种作为治疗眼科疾病的新化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| CN106336397A (zh) * | 2015-07-07 | 2017-01-18 | 郭明山 | 一种作为治疗眼科疾病的新化合物 |
| CN106478596A (zh) * | 2015-08-25 | 2017-03-08 | 李建成 | 一种作为治疗眼科疾病的新化合物 |
| WO2019196945A1 (fr) * | 2018-04-13 | 2019-10-17 | 成都海创药业有限公司 | Nouveau procédé de synthèse d'amides deutérés et de sulfonamides deutérés |
-
2020
- 2020-08-28 CA CA3147801A patent/CA3147801A1/fr active Pending
- 2020-08-28 AU AU2020338490A patent/AU2020338490A1/en active Pending
- 2020-08-28 WO PCT/CA2020/051177 patent/WO2021035360A1/fr unknown
- 2020-08-28 EP EP20857153.9A patent/EP4021912A4/fr active Pending
-
2022
- 2022-02-22 IL IL290798A patent/IL290798A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106317017A (zh) * | 2015-07-10 | 2017-01-11 | 李建成 | 一种作为治疗眼科疾病的新化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020338490A1 (en) | 2022-03-17 |
| IL290798A (en) | 2022-04-01 |
| EP4021912A1 (fr) | 2022-07-06 |
| CA3147801A1 (fr) | 2021-03-04 |
| WO2021035360A1 (fr) | 2021-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781564A4 (fr) | Composés pour le traitement d'un cancer | |
| EP3758706A4 (fr) | Inhibiteurs de la kinase wee1 et méthodes de traitement du cancer à l'aide de ces inhibiteurs | |
| EP4079735A4 (fr) | Composé pour inhiber et induire la dégradation de la kinase egfr | |
| EP3804707A4 (fr) | Inhibiteur de kinase | |
| IL288522A (en) | Inhibitor of egfr for cancer treatment | |
| EP4085053A4 (fr) | Traitement du cancer avec des inhibiteurs de cdk12/13 | |
| EP3500257A4 (fr) | Composés inhibiteurs de kinase, compositions et méthodes de traitement du cancer | |
| EP3781584A4 (fr) | Promédicaments de 4'-thio-nucléotide et de nucléoside pour le traitement du cancer | |
| EP3927700A4 (fr) | Inhibiteurs de kinases | |
| IL286727A (en) | fgfr tyrosine kinase inhibitors for the treatment of urinary tract carcinoma | |
| EP4081527A4 (fr) | Association d'un inhibiteur de kinase 7 dépendante de cyclines et d'une immunothérapie pour le traitement du cancer | |
| EP3892282A4 (fr) | Association pour le traitement du cancer | |
| EP3956035A4 (fr) | Composés contre le cancer portant des mutations egfr résistantes aux inhibiteurs de la tyrosine kinase | |
| EP3787625A4 (fr) | Méthodes de traitement du cancer | |
| EP3843773A4 (fr) | Inhibition de kinases ripk pour traiter des maladies neurodégénératives | |
| EP3962919A4 (fr) | Composés pour traiter le cancer | |
| EP3630080A4 (fr) | Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer | |
| IL312650A (en) | CDK4 inhibitor for cancer treatment | |
| EP3966208A4 (fr) | Composés et méthodes de traitement du cancer | |
| EP3781215A4 (fr) | Méthodes de traitement du cancer | |
| EP3984553A4 (fr) | Composition pour prévenir ou traiter le cancer | |
| EP3893882A4 (fr) | Inhibiteurs de cxcr7 destinés au traitement du cancer | |
| EP3852816A4 (fr) | Méthodes de traitement de cancer | |
| EP3774799C0 (fr) | Inhibiteurs de nek6-kinase utiles pour le traitement de tumeurs solides | |
| EP4021912A4 (fr) | Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220322 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20230725 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 405/12 20060101ALI20230719BHEP Ipc: C07D 401/14 20060101ALI20230719BHEP Ipc: C07D 401/06 20060101ALI20230719BHEP Ipc: A61P 35/00 20060101ALI20230719BHEP Ipc: A61K 31/675 20060101ALI20230719BHEP Ipc: A61K 31/4439 20060101ALI20230719BHEP Ipc: C07F 9/6558 20060101AFI20230719BHEP |